Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00003461
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : August 21, 2014
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Duke University

November 1, 1999
January 27, 2003
August 21, 2014
February 1998
February 2005   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00003461 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Phase I Study of At-Labeled Anti-Tenascin Human/Mouse Chimeric Monoclonal Antibody 81C6 (ch81C6) Via Surgically Created Cystic Resection Cavity in the Treatment of Patients With Primary or Metastatic Brain Tumors

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. This may be effective treatment for primary or metastatic brain tumors.

PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients with primary or metastatic brain tumors.


  • Determine the toxicity of monoclonal antibody (MAb) Astatine At 211 Antitenascin Human/Mouse Chimeric 81C6 (At 211 MAb 81C6) therapy delivered via the intracranial resection cavity in patients with recurrent primary or metastatic malignant brain tumors.
  • Identify objective therapeutic responses of these patients to this treatment.

OUTLINE: This is a dose escalation study.

Patients undergo surgical resection of their tumor at which time an indwelling intracranial resection cavity catheter is surgically placed. Patients receive one dose of astatine At 211 antitenascin monoclonal antibody 81C6 (At 211 MAb 81C6) via the intralesional catheter.

Cohorts of 3-6 patients are treated at escalating doses of At 211 MAb 81C6. The maximum tolerated dose is the highest dose at which no more than 3 of 6 patients experience dose limiting toxicity.

Patients are followed initially at 4 weeks, then at approximately 12 weeks, at 24 weeks, and then every 12 weeks for 1 year.

PROJECTED ACCRUAL: A total of 12-24 patients will be accrued for this study within 18-24 months.

Phase 1
Phase 2
Primary Purpose: Treatment
  • Brain and Central Nervous System Tumors
  • Metastatic Cancer
  • Neuroblastoma
  • Procedure: surgical procedure
  • Radiation: astatine At 211 monoclonal antibody 81C6
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
February 2005
February 2005   (Final data collection date for primary outcome measure)


  • Histologically confirmed newly diagnosed or recurrent supratentorial primary or metastatic malignant brain tumor
  • Measurable disease by MRI or CT scan

    • Candidate for surgical resection
    • Extension of tumor no more than 1.0 cm beyond the margin of the surgical cavity
  • Demonstrated reactivity of tumor cells with tenascin by immunohistology with either a polyclonal rabbit antibody or the monoclonal mouse antibody
  • No infratentorial tumors, diffusely infiltrating tumors, tumors with subependymal spread, or multifocal tumors



  • 18 and over

Performance status:

  • Karnofsky 50-100%

Life expectancy:

  • Not specified


  • Absolute neutrophil count greater than 1000/mm^3
  • Platelet count greater than 100,000/mm^3


  • Bilirubin less than 1.5 mg/dL
  • Alkaline phosphatase less than 1.5 times normal
  • SGOT less than 1.5 times normal


  • Creatinine less than 1.2 mg/dL


  • Not pregnant or nursing
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • At least 6 weeks since prior chemotherapy, unless unequivocal evidence of progression

Endocrine therapy:

  • Concurrent corticosteroids allowed, but must be on stable dose for at least 1 week


  • At least 3 months since prior radiotherapy to site of measurable disease in the CNS


  • See Disease Characteristics
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Duke University
Duke University
National Cancer Institute (NCI)
Study Chair: Darell D. Bigner, MD, PhD Duke Cancer Institute
Duke University
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP